MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 05-14-2026
AstraZeneca PLC Total Assets 2011-2026 | AZN
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets AstraZeneca PLC
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 114 B | 104 B | 101 B | 96.5 B | 105 B | 66.7 B | 61.4 B | 60.7 B | 63.4 B | 62.5 B | 60.1 B | 58.6 B | 55.9 B | 53.5 B | 52.8 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 114 B | 52.8 B | 74.4 B |
Quarterly Total Assets AstraZeneca PLC
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 114 B | 112 B | 104 B | 104 B | 101 B | 96.5 B | - | - | - | - | 105 B | - | 73.6 B | - | 66.7 B | - | 59.9 B | - | 61.4 B | - | 61.9 B | - | 60.7 B | - | 61.3 B | - | 63.4 B | - | 65.1 B | - | 62.5 B | - | - | - | 60.1 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 114 B | 59.9 B | 79.7 B |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
11.2 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
35.6 M | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
6.95 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M | China |
 |
Deciphera Pharmaceuticals
DCPH
|
474 M | - | - | $ 2.18 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | France |
 |
Compugen Ltd.
CGEN
|
157 M | $ 2.24 | 2.28 % | $ 209 M |  Israel |
 |
BioNTech SE
BNTX
|
22 B | $ 90.06 | 1.82 % | $ 21.8 B | Germany |
 |
Coherus BioSciences
CHRS
|
258 M | $ 1.58 | 7.42 % | $ 185 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
92.2 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
99.6 M | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
1.06 B | - | - | $ 4.9 B |  Britain |
 |
Galera Therapeutics
GRTX
|
7.2 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
18.2 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Affimed N.V.
AFMD
|
97.2 M | - | -34.95 % | $ 21.5 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
78.8 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
19.7 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
226 M | - | -7.31 % | $ 87 M | USA |
 |
Celldex Therapeutics
CLDX
|
583 M | $ 30.18 | 1.38 % | $ 2 B | USA |
 |
Generation Bio Co.
GBIO
|
231 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
31.3 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
2.33 B | $ 0.79 | -6.59 % | $ 36.1 M | Israel |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M | Israel |
 |
Esperion Therapeutics
ESPR
|
466 M | $ 3.14 | -0.16 % | $ 653 M | USA |
 |
Eton Pharmaceuticals
ETON
|
92.1 M | $ 28.89 | 4.64 % | $ 777 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
8.18 M | - | -4.36 % | $ 27 M | USA |
|
Forte Biosciences
FBRX
|
82.8 M | $ 16.48 | -3.09 % | $ 213 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
86.6 M | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
1.66 B | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
190 M | $ 14.83 | 2.88 % | $ 213 M | USA |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
21.4 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
113 M | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.51 M | $ 3.14 | 0.96 % | $ 5.17 M | Israel |
 |
Aptose Biosciences
APTO
|
10 M | - | -45.71 % | $ 1.2 M | Canada |
 |
CRISPR Therapeutics AG
CRSP
|
2.27 B | $ 57.06 | 9.56 % | $ 5.13 B |  Schweiz |
 |
Aptinyx
APTX
|
66.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | USA |
 |
Galectin Therapeutics
GALT
|
19.5 M | $ 2.35 | -0.21 % | $ 150 M | USA |